Highest-materiality recent filing
Ainos Q2 2026: no financials; AI Nose deployments expand; $2.1M commercial arrangement
No revenue or EPS figures provided in the press release; only qualitative business update.
Ainos dismisses YCM CPA as auditor, engages DLEE Accountancy as new independent auditor
Dismissed YCM CPA INC. as independent registered public accounting firm on July 9, 2026, following expiration of engagement.
Credit facility of NT$62,000,000 (approx US$1,937,800) from CTBC Bank.
Operating expenses declined ~30% YoY to approximately $2.28 million for Q1 2026.
Ainos FY2025 revenue up 499%, gross margin 82.9%; AI Nose deployments scaling in semiconductor
Revenue up ~499% YoY; gross margin improved to 82.9% from a gross loss in 2024.
Ainos grants distribution rights to Trusval Technology for AI Nose products
Three-year distribution agreement with Trusval Technology Co. Ltd. for AINOS AI Nose and related products.
Proprietary AI Nose hardware generates repeatable scent data for large-scale AI training.
Ainos issues 1.16M shares of common stock to wholly owned subsidiary ScentAI
Issued 1,160,000 shares of AIMD common stock to ScentAI Inc. in exchange for 116,000,000 ScentAI shares.
Ainos Q3 2025 results omit financials; focuses on AI Nose partnerships and patents
No net revenue or EPS disclosed in Q3 2025 press release; SG&A down 22% YoY, total opex down 8%.
Ainos extends patent license fee term to two years at $50,000/month with TCNT
Fourth addendum to Product Development Agreement with Taiwan Carbon Nano Technology (TCNT) signed Oct 15, 2025.
Ainos files prospectus supplement for $874,496 ATM stock offering
Company filed prospectus supplement on Sept 5, 2025 to sell up to $874,496 in common stock via ATM agreement with H.C. Wainwright.
Ainos Q2 2025 results highlight $2.1M AI Nose order and commercial momentum
Secured $2.1M three-year subscription order from ASEH for AI Nose in semiconductor manufacturing.
Ainos secures $2.1M order with ASE for AI Nose deployment in semiconductor manufacturing
Three-year subscription order valued at $2.1M from ASE Technology Holding, the world's largest semiconductor assembly and test provider.
Ainos appoints new auditor YCM CPA after KCCW resignation
KCCW resigned as independent auditor on July 30, 2025, citing exit from public company audit practice.
Ainos regains Nasdaq compliance; sets 90-day AI Nose scale plan with 412% Q1 revenue jump
Nasdaq confirmed compliance on July 15, 2025; closing bid price >= $1.00 for 10 consecutive days.
Ainos effects 1-for-5 reverse stock split effective June 30, 2025
Reverse stock split at 1:5 ratio effective 5:01 a.m. Central on June 30, 2025.
Ainos forms strategic partnership with Kenmec to deploy AI Nose in smart factories
Legally binding strategic partnership announced June 24, 2025.
Revenue up 412% YoY to $106,207; gross profit of $87,974 vs prior-year gross loss of $6,025.
Ainos extends maturity of $1M convertible note to May 13, 2025
Original $1,000,000 convertible note issued March 13, 2023 with 6% compounded interest.
Ainos amends convertible note: maturity extended to 2027, conversion price floor lowered to $4.50
Maturity extended from ~March 2025 to March 12, 2027; principal $2M at 6% compounded interest unchanged.
Ainos signs MOU with ASE to deploy AI Nose for semiconductor VOC detection
Ainos (AIMD) and Advanced Semiconductor Engineering (ASE) signed a legally binding MOU to integrate AI Nose into ASE's 46 fully automated factories.
Ainos reports FY2024 revenue $20,729, net loss $14.9M; AI Nose and VELDONA progress
Revenue fell 83% YoY to $20,729; cost of revenues $52,595; gross loss narrowed to $31,866.
Ainos partners with ugo to integrate AI Nose into robots for scent detection
Ainos (AIMD) and ugo, Japan's largest service robot firm, to develop first smell-enabled robot.
Ainos signs non-binding MOU with Taiwan Tanabe for VELDONA manufacturing and Taiwan market
Non-binding MOU with Taiwan Tanabe Seiyaku (Mitsubishi Tanabe subsidiary) for exclusive marketing, manufacturing, and marketing authorization of VELDONA in Taiwan.
Third Addendum to Product Development Agreement adds nitrogen-oxygen separation machine for medical oxygen and wound healing.
Ainos shareholders ratify auditor, approve 2M share special stock award at annual meeting
Ratification of KCCW Accountancy Corp. as auditor approved with 5,062,909 for, 52,319 against.
Issued 5.5M shares to TCNT for exclusive, irrevocable, perpetual license of gas-sensor and medical-device patents.
Ainos Q2 2024 net loss widens to $3.2M; revenues nil; FCGS trial begins
Revenues nil vs $28,555 YoY as COVID-19 test kit sales ceased; net loss $3,195,022 vs $2,349,727.
Ainos receives Nasdaq deficiency notice for bid price below $1; 180 days to cure
Nasdaq notified Ainos that its common stock bid price closed below $1.00 for 30 consecutive business days.
Ainos extends patent license with TCNT for three months at $95k/month
Second Addendum extends non-exclusive patent use for VOC/POCT tech from July to Sept 2024.
Clinical trials for AI Nose-powered Ainos Flora achieved 75 meaningful case results, validating AI algorithm model.
Ainos Q1 revenue down 58% YoY to $20.7K; net loss widens to $3.3M; secures $9M convertible note
Revenue of $20,729 in Q1 2024, down 58% from $49,164 in Q1 2023, due to pivot from COVID-19 test kits.
Ainos issues $9M convertible note to ASE Test, with warrant for 500k shares
$9,000,000 convertible note, 6% compound interest, matures May 3, 2027.
Ainos appoints Christopher Hsin-Liang Lee as CFO, effective March 18, 2024
Mr. Lee named CFO; over 25 years of accounting/finance experience including 10 years as CFO of a Nasdaq-listed company.
CFO Meng-Lin Sung resigns effective March 13, 2024; no replacement named
Meng-Lin Sung resigned as CFO of Ainos, Inc. effective March 13, 2024.
Ainos reports FY2023 revenue drop to $122K; net loss $13.8M
Revenue fell 97% to $122,112 from $3.52M in 2022, driven by COVID-19 test kit sales decline.
Ainos submits clinical hold complete response to FDA for VELDONA Phase 2 COVID-19 trial
Submitted clinical hold complete response to FDA for Phase 2 trial of low-dose oral IFN-alpha VELDONA for mild COVID-19.
Ainos secures $1.75M additional funding via amended convertible note with Lind Global
$1.75M total, $875k funded at closing; $875k subject to registration statement conditions.
Addendum specifies co-development products: VOC diagnostics, AI Nose, POCT, VELDONA drug processing, lateral flow diagnostics.
Ainos regains compliance with Nasdaq Rule 5550(a)(2) after bid price recovers
Nasdaq notified Ainos on Dec 29, 2023 that it regained compliance with the minimum bid price requirement.
Ainos Chief Legal Counsel and Corporate Secretary John Junyong Lee resigns
John Junyong Lee resigned as Chief Legal Counsel and Corporate Secretary effective December 20, 2023.
Reverse stock split at 1-for-5 ratio effective Dec 14, 2023; fractional shares paid in cash.
Ainos implements 1-for-5 reverse stock split effective December 14, 2023
Reverse split ratio 1:5; new shares trade Dec 14 under same ticker AIMD with new CUSIP 00902F303.
Ainos stockholders ratify auditor, approve say-on-pay, and opt for triennial advisory votes
Ratified KCCW Accountancy Corp. as auditor for FY2023: 78.15% FOR, 0.58% AGAINST.
Ainos issues 3,000,000 shares of common stock as Special Stock Awards to officers and directors
3M shares issued unregistered under Section 4(a)(2)/Reg D to nine insiders.
Ainos Q3 2023 revenue drops 98.6% to $24.5K; net loss narrows to $3.0M
Revenue fell to $24,489 from $1,757,774 in Q3 2022 due to COVID-19 test kit demand decline.
Ainos enters $10M private placement with Lind Global; initial $3M tranche funded
Initial closing: $2M funded now; remaining $1M subject to shareholder approval and SEC registration.
Ainos extends two promissory notes: $300K KY Note to March 2025, $42K i2China Note to Sept 2024
KY Note extended to March 31, 2025; unpaid principal $300K plus accrued interest at 1.85%.
Ainos Q2 revenue collapses to $28.6K; net loss widens to $2.35M
Revenue dropped ~95% YoY to $28,555 from $636,627 due to COVID slowdown in Taiwan.
Ainos signs co-development deal with Nisshinbo & Inabata for VOC sensing platform
Ainos will receive one-time upfront development fee plus per-unit fees for AI Nose tech.
As of August 9, 2024, Lawrence K. Lin transitioned from his role as the Company’s Executive Vice President of Operations, effective August 9, 2024.
On March 15, 2024, the Board of Directors appointed Christopher Hsin-Liang Lee as the Chief Financial Officer of Ainos, Inc. (the “Company”).
On March 13, 2024, Meng-Lin Sung, the Chief Financial Officer of Ainos, Inc. (the “Company”), resigned from her positions with the Company, effective as of such date.
On May 17, 2023, the Board of Directors appointed Meng-Lin Sung (Amanda) as the Chief Financial Officer of the Company.
On May 16, 2023, Ms. Hui-Lan (Celia) Wu retired as the CFO of the Company.
On June 15, 2022, the Board appointed Pao-Sheng Wei to the Board, the Compensation Committee, and the Audit Committee and as Chairman of the Audit Committee and as an Audit Committee Financial Expert.
On June 15, 2022, the Board accepted the resignation of Hsiu-Chen Chiu from the Board, the Compensation Committee, the Audit Committee and as Audit Committee Chairperson.
On June 15, 2022, the Board appointed Pao-Sheng Wei to the Board, the Compensation Committee and as Chairman of the Compensation Committee, and the Audit Committee and as Chairman of the Audit Committee and as an Audit Committee Financial Expert.
On June 15, 2022, the Board accepted the resignation of Hsiu-Chen Chiu from the Board, the Compensation Committee and as Chairperson of the Compensation Committee, and the Audit Committee and as Audit Committee Chairperson.
Mr. John Junyong Lee, Esq. age 54, was re-appointed as Chief Legal Counsel and Corporate Secretary of the Company.
Mr. Chun-Hsien Tsai resigned as Chief Financial Officer (CFO) and the vacancy was filled by the election of his successor, Ms. Hui-Lan (Celia) Wu.
Mr. Lawrence K. Lin, age 51, was elected to serve as Executive Vice President of Operations of the Company.
Max materiality 0.75 · Median 0.55 · Most common event other_material